SCHEMBL3370351

SCHEMBL3370351

COCC(=O)N1CCCC1c1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.54
HCRTR1 O43613 10/20 0.49
HCRTR2 O43614 10/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
CPT1A P50416 2/20 0.48
ALDH1A1 P00352 3/20 0.46
ALOX15B O15296 1/20 0.46
RAB9A P51151 1/20 0.46
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KCNH2 Q12809 1/20 0.42
MCHR1 Q99705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369456 0.90 HCRTR1 (0.54) HSD11B1HCRTR1HCRTR2CPT1AALDH1A1
SCHEMBL3369975 0.86 HSD11B1 (0.52) HSD11B1HCRTR1HCRTR2SMN1; SMN2CPT1A
SCHEMBL3366773 0.86 CPT1A (0.66) HSD11B1CPT1A
SCHEMBL3366654 0.85 HSD11B1 (0.51) HSD11B1HCRTR1HCRTR2SMN1; SMN2CPT1A
SCHEMBL3365286 0.84 CPT1A (0.61) HSD11B1HCRTR1HCRTR2CPT1A
SCHEMBL3366771 0.83 CPT1A (0.53) HSD11B1HCRTR1HCRTR2CPT1AALDH1A1
SCHEMBL30867244 0.82 TSHR (0.60) HSD11B1HCRTR1HCRTR2ALDH1A1LMNA
SCHEMBL3366749 0.82 HSD11B1 (0.52) HSD11B1HCRTR1HCRTR2SMN1; SMN2ALDH1A1
SCHEMBL3369944 0.82 HSD11B1 (0.50) HSD11B1HCRTR1HCRTR2SMN1; SMN2CPT1A
SCHEMBL3367292 0.81 HCRTR1 (0.50) HSD11B1HCRTR1HCRTR2CPT1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C HSD11B1 545/4885HCRTR1 461/4885HCRTR2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.